论文部分内容阅读
对Ⅱ、Ⅲ期乳腺癌６９例综合方法疗效对比分析。全组５年生存率５３６％，Ⅱ期７８％，Ⅲ期４７２％，Ⅱ期各组（Ｓ，Ｓ＋Ｃ，Ｓ＋Ｒ，Ｓ＋Ｒ＋Ｃ）无显著差别；Ⅲ期各组Ｓ１４２％，Ｓ＋Ｃ３３％，Ｓ＋Ｒ４７３％，Ｓ＋Ｒ＋Ｃ６０％（Ｐ＜００５）说明综合治疗方法对生存率有影响，增加放疗对Ⅲ期尤为显著；加放组淋巴区胸壁３年复发率与未加放组比为１∶２（９／５０：７／１９），其复发平均时间为３１８∶１３５（月），说明加放对局部控制效果的肯定。增加化疗（ＣＭＦ／ＣＡＦ／ＣＥＦ）与未加化疗比生存率有改变，前者为５９５％（２２／３７），后者为３３３％（３／９），而除Ｓ组外，增加化疗使Ｓ＋Ｒ＋Ｃ达６０％，Ｓ＋Ｒ４７３％组无显著性差别（０２５＞Ｐ＞０１０）。Ｓ＋（Ｓ＋Ｃ）与（Ｓ＋Ｒ）＋（Ｓ＋Ｒ＋Ｃ）组５年生存率，前者为３６８％（７／１９），后者为６０％（３０／５０）。
The comparative analysis of the comprehensive curative effect of 69 cases of stage II and stage III breast cancer. The 5-year survival rate was 53.6% in the whole group, 78% in phase II, 47.5% in phase III, and there was no significant difference in phase II (S, S+C, S+R, S+R+C); in phase III, S142%, S+C33. %, S+R473%, S+R+C60% (P<005) showed that comprehensive treatment had an effect on survival rate. Increased radiotherapy was particularly significant for phase III; the recurrence rate of chest wall in the lymph node plus/discharge group for 3 years was higher than that of non-addition group. For 1:2 (9/50:7/19), the average recurrence time is 318:135 (months), which indicates that the effect of local control is added and released. The survival rate of patients with increased chemotherapy (CMF/CAF/CEF) vs. no chemotherapy was changed, the former was 59.5% (22/37), and the latter was 33. 3% (3/9), with the exception of S. The addition of chemotherapy increased the S+R+C by 60%. There was no significant difference between the S+R473% groups (025>P>010). The 5-year survival rate of the S+(S+C) and (S+R)+(S+R+C) groups was 36.8% (7/19) in the former and 60% (30/50) in the latter.